Newborn Screening for Spinal Muscular Atrophy Introduced in Alberta and Saskatchewan
We are excited to share that through the advocacy efforts of Muscular Dystrophy Canada (MDC), in the past week both Saskatchewan and Alberta’s provincial governments have implemented newborn screening (NBS) programs for Spinal Muscular Atrophy (SMA)!
On February 23rd, Saskatchewan officially expanded their newborn screening panel to include testing for SMA as part of its newborn screening program, and on February 28th Alberta announced that through a pilot project with MDC, newborns will be able to be screened for SMA.
MDC continues to work diligently with donors, provincial governments, partners and supporters to remove barriers so that screening for SMA in Canada is a reality. Read more about MDC’s multi-year, multi-phase endeavour in collaboration with Novartis Pharmaceuticals Canada Inc. to better understand and address barriers for the implementation of newborn screening for spinal muscular atrophy (SMA).
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.